OR WAIT null SECS
November 03, 2014
Bristol-Myers Squibb entered into an agreement with Galecto Biotech AB to gain exclusive rights to TD139, a novel inhaled inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis.
October 31, 2014
Amgen is suing Sandoz over Sandoz's biosimilar application for filgrastim.
October 30, 2014
Sigma-Aldrich's custom manufacturing services business unit, SAFC, has launched a new protein quality supplement for biological drug production, including biosimilars.
October 29, 2014
The new Argos biomanufacturing facility in North Carolina will include automated production using the company's Arcelis technology.
The board of directors at Sanofi unanimously agree to remove Sanofi's CEO.
October 27, 2014
The divestment will create the number two player in the global influenza vaccine industry.
October 17, 2014
Lilly announces the closure of its Guayama, Puerto Rico manufacturing facility amid continued investments at other plants.
Boehringer Ingelheim's OFEV was approved by FDA as the first treatment for idiopathic pulmonary fibrosis, a fatal lung disease.
Genentech announced FDA-approved Esbriet for the treatment of Idiopathic Pulmonary Fibrosis.
October 16, 2014
The company submits an orphan drug application to FDA for its Cell-in-a-Box treatment for pancreatic cancer.